EGFR and colorectal carcinoma: Then, NPOT analysis of panitumumab interactome in metastatic versus non‐metastatic tumors demonstrated that EGFR was exclusively present in metastatic tumors, suggesting a distinct EGFR‐driven signaling landscape in advanced CRC (Figures 4 and 5).